Charles River Laboratories International Inc. (NYSE:CRL) Director C Richard Reese sold 4,539 shares of the business’s stock in a transaction on Monday, November 28th. The stock was sold at an average price of $71.93, for a total value of $326,490.27. Following the completion of the transaction, the director now owns 44,943 shares of the company’s stock, valued at approximately $3,232,749.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Charles River Laboratories International Inc. (NYSE:CRL) opened at 71.10 on Thursday. The stock has a 50 day moving average price of $75.67 and a 200-day moving average price of $81.76. Charles River Laboratories International Inc. has a 1-year low of $65.70 and a 1-year high of $89.18. The company has a market cap of $3.37 billion, a price-to-earnings ratio of 24.03 and a beta of 1.18.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.13 by $0.05. Charles River Laboratories International had a return on equity of 25.31% and a net margin of 9.05%. The firm earned $425.70 million during the quarter, compared to analyst estimates of $291.20 million. During the same quarter in the prior year, the business posted $1.03 EPS. The business’s revenue for the quarter was up 21.8% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International Inc. will post $4.47 EPS for the current year.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/12/01/c-richard-reese-sells-4539-shares-of-charles-river-laboratories-international-inc-crl-stock.html.

Several hedge funds have recently modified their holdings of the stock. Emerald Acquisition Ltd. acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at approximately $37,018,000. FMR LLC raised its stake in shares of Charles River Laboratories International by 19.5% in the second quarter. FMR LLC now owns 2,158,477 shares of the company’s stock valued at $177,945,000 after buying an additional 351,630 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Charles River Laboratories International by 124.2% in the second quarter. Principal Financial Group Inc. now owns 497,895 shares of the company’s stock valued at $41,047,000 after buying an additional 275,785 shares in the last quarter. Redwood Investments LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at approximately $14,493,000. Finally, Fiera Capital Corp acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at approximately $14,424,000. Hedge funds and other institutional investors own 97.17% of the company’s stock.

Several analysts recently commented on the company. Barclays PLC raised Charles River Laboratories International from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $65.00 to $77.00 in a report on Wednesday. Citigroup Inc. lifted their price objective on Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Thursday, August 4th. Jefferies Group lifted their price objective on Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Wednesday, October 5th. Finally, Bank of America Corp. set a $93.00 price objective on Charles River Laboratories International and gave the stock a “buy” rating in a report on Friday, November 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $85.96.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.